Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2000-10-01
Metadata
Show full item recordCitation
Scand. J. Rheumatol. 2000, 29(5):323-5Abstract
In this retrospective analysis of the DMARD CPH 82 in 44 Icelandic patients with severe refractory arthritis, clinical tolerance was good and serious side effects absent, although the majority were using the drug in combination with other DMARDS. Side effects leading to discontinuation were seen in 16% and the three year drug-survival was 51%.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAdditional Links
http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=4103578&site=ehost-liveCollections
Related articles
- CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA.
- Authors: Bjørneboe O, Moen F, Nygaard H, Haavik TK, Svensson B
- Issue date: 1998
- Difference in pharmacological activity between CPH 82 and podophyllotoxin.
- Authors: Rosén B
- Issue date: 1998
- Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
- Authors: Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG
- Issue date: 2007 Oct
- Glucocorticoid-like anti-inflammatory versus immunosuppressive effects of CPH 82 as a single drug therapy of moderately active rheumatoid arthritis patients.
- Authors: Masi AT, Chatterton RT
- Issue date: 2000
- CPH 82.
- Issue date: 2003